CD24/4-1BB Antigen-Binding Protein for ADCC, ADCP, and T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor immunotherapy methods lack bispecific antigen binding proteins that can effectively target both CD24 and 4-1BB to activate NK cells and macrophages for ADCC and ADCP effects, activate CD8+ T cells, kill regulatory T cells, and enhance anti-tumor responses.
Innovation Solution
Development of a bispecific antigen binding protein that specifically recognizes CD24 and 4-1BB, activating the 4-1BB signaling pathway, enhancing ADCC and ADCP effects on tumor cells, and promoting CD8+ T cell infiltration to overcome immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a bispecific antigen binding protein targeting both CD24 and 4-1BB is developed, then anti-tumor efficacy is improved through multiple mechanisms (ADCC, ADCP, T cell activation), but the complexity of the therapeutic agent increases
Solution Approach 1:
The patent combines two antibody specificities (anti-CD24 and anti-4-1BB) into a single bispecific antigen binding protein molecule. This merging allows the therapeutic agent to simultaneously engage multiple immune cell types (NK cells, macrophages, and T cells) through its dual binding capability, achieving enhanced anti-tumor efficacy through multiple mechanisms in one agent
Solution Approach 2:
The bispecific antigen binding protein is designed to perform multiple functions simultaneously: it can bind to CD24 on tumor cells to enable ADCC and ADCP effects, while also binding to 4-1BB to activate T cells and lift immunosuppression. This multi-functionality allows a single therapeutic agent to address multiple aspects of tumor immunity
2Reliability
If the bispecific antigen binding protein activates multiple immune mechanisms simultaneously, then the anti-tumor response is enhanced, but the mechanism of action becomes more complex
Solution Approach 1:
The patent segments the anti-tumor immune response into distinct functional domains within the bispecific protein structure. The anti-CD24 binding region facilitates ADCC and ADCP mechanisms by engaging Fc receptors on NK cells and macrophages, while the anti-4-1BB binding region independently activates T cells through costimulatory signaling. This segmentation allows each mechanism to operate through its dedicated binding interface
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bispecific antigen binding protein effectively kills CD24-expressing tumor cells, activates CD8+ T cells, and enhances anti-tumor responses by lifting immunosuppression and promoting CD8+ T cell infiltration.
Implementation Method 1
a first antibody or antigen binding fragment thereof that specifically binds to a first antigen; and a second antibody or antigen binding fragment thereof that specifically binds to a second antigen; wherein: the first antigen is CD24, and the second antigen is 4-1BB
Data Source
AI summary
A bispecific antigen binding protein, including (a) a first antibody or antigen binding fragment thereof that specifically binds to a first antigen; and (b) a second antibody or antigen binding fragment thereof that specifically binds to a second antigen. In the embodiments, the first antigen is CD24, and the second antigen is 4-1BB; or, the first antigen is 4-1BB, and the second antigen is CD24.